Three new psychedelic stocks are trading publicly. One commenced trading last week, two more are coming this week.
Psychedelics
COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care
Compass joins an international organization dedicated to advancing psychedelic drug research.
Entheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from the Canadian Securities Exchange
Entheon Biomedical has announced that it expects to commence public trading on or about November 12th, symbol "ENBI".
Pure Extracts Technologies Corp. Commences Trading on the Canadian Securities Exchange (CSE)
Pure Extracts is now trading under the symbol "PULL".
Field Trip Health Ltd. Prepares to Enter Oregon Market following the Passage of Measure 109 in Oregon, Creating the First Legal Market for Psilocybin Services
Field Trip plans to enters Oregon's medicinal market for psilocybin-assisted psychotherapy.
Cybin Completes Reverse Take-Over Transaction
Cybin Corp has completed its RTO and received approval to commence trading on the NEO Exchange (symbol "CYBN") and expects to begin trading on or about November 10th.
What Oregon Psilocybin Legalization Means For The Psychedelic Drug Industry
Oregon has legalized the medicinal use of psilocybin. Here is why that's big news for the psychedelic drug industry.
Psychedelics Revolution Front-and-Center As Americans Prepare To Vote
On the eve of the U.S. election, psychedelic drugs are a high-profile election issue.
Pure Extracts Technologies Corp. to Commence Trading on the Canadian Securities Exchange (CSE)
Pure Extracts Corp. is an extraction specialist targeting the cannabis, psychedelics and functional mushrooms sectors and will trade on the CSE under the symbol "PULL".
MindMed Announces the Completion of Phase 1 Study Measuring Dosing Effects of LSD
This dosing study on LSD will be utilized as MindMed prepares for its Phase 2b clinical trial of LSD for anxiety.
MindMed Has $50 Million In The Bank As It Looks Ahead To NASDAQ Uplisting
With an industry-leading psychedelic drug R&D portfolio, MindMed has plenty of options to leverage its cash-on-hand to a higher share price.
MindMed Closes Upsized Financing of CAD $28.75m With Strong Institutional Demand for Psychedelic Medicines
With MindMed's latest financing, total cash reserves now stand at CAD$50.1 million.
Champignon Brands Provides Update on Continuous Disclosure Review
Champignon Brands is hopeful that the B.C. Securities Commission is close to revoking its Cease Trade Order for SHRM.
Field Trip Health Ltd. Provides Update on FT-104, Its Next Generation Psychedelic Molecule in Development
Field Trip's new psychedelic molecule, FT-104, is showing similar efficacy to psychedelics like psilocybin -- but with shorter duration.
Psychedelic Stocks Offer Great Buying Opportunity In Weak Markets
Markets are tumbling. Where do you want to be positioned AFTER the selloff is over? Psychedelic stocks.